PATENT COOPERATION TREATY REC'D 10 AUG 2004

PCT

REC'D 10 AUG 2004

INTERNATIONAL PRELIMINARY EXAMINATION REPORT


(PCT Article 36 and Rule 70)

Applicant's or agent's file reference P11676PC00	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).				
International Application No.	International Filing Date (day/month/year)					
PCT/AU2003/001582	27 November 2003	27 November 2002				
International Patent Classification (IPC) or	national classification an	d IPC				
Int. Cl. 7 G06F 17/60						
Applicant						
ILIFE DATA PTY LIMITED et al						
1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.						
2. This REPORT consists of a total of 3	sheets, including this co	over sheet				
This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).						
These annexes consist of a total of	f sheet(s).					
3. This report contains indications relating to the following items:						
I X Basis of the report						
II Priority						
III Non-establishment of oni	<u> </u>					
	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability					
= son of amely of invention	Lack of unity of invention					
V X Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement						
VI Certain documents cited						
VII Certain defects in the inter	Pertain defects in the international application					
	Certain observations on the international application					
	- International applicant)II				
Date of submission of the demand		ate of completion of the report				
11 May 2004		30 July 2004				
Name and mailing address of the IPEA/AU		uthorized Officer				
AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA						
3-mail address: pct@ipaustralia.gov.au						
, (02) 0203 3929		ROSEMARY LONGSTAFF Telephone No. (02) 6283 2637				
<u> </u>						

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

	В	Basis of the report		
		th regard to the elements of the international application:*		
	X	the international application as originally filed.		
		the description, pages , as originally filed,		
		pages, filed with the demand,		
		pages, received on with the letter of		
		the claims, pages, as originally filed,		
		pages, as amended (together with any statement) under Article 19,		
	•	pages , filed with the demand,		
	\Box	pages, received on with the letter of the drawings, pages, as originally filed,		
	ш			
		pages, filed with the demand, pages, received on with the letter of		
		the sequence listing part of the description:		
	ل	pages , as originally filed	ļ	
		pages, filed with the demand		
		pages, received on with the letter of		
	which	Tith regard to the language, all the elements marked above were available or furnished to this Authority in the language in hich the international application was filed, unless otherwise indicated under this item. hese elements were available or furnished to this Authority in the following language which is: the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).		
	Ħ	the language of publication of the international application (under Rule 48.3(b)).		
		the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).	i	
.		Vith regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:		
		contained in the international application in written form.		
		filed together with the international application in computer readable form.		
	\sqcap	furnished subsequently to this Authority in written form.		
	H	furnished subsequently to this Authority in computer readable form.		
		The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.		
		The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished		
١		The amendments have resulted in the cancellation of:		
	_	the description, pages		
		the claims, Nos.		
		the drawings, sheets/fig.		
5.		This report has been established as if (some of) the amendments had not been made, since they have been considered to		
	<u> </u>	go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**	_	
*	Re rej	Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).		
**	An	replacement sheet containing such amendments must be referred to under item 1 and annexed to this report		

INTERNATIONAL PREMINARY EXAMINATION REPORT



V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1.	Statement		
	Novelty (N)	Claims 1-31	YES
		Claims	. NO
	Inventive step (IS)	Claims 1-31	YES
		Claims	NO
	Industrial applicability (IA)	Claims 1-31	YES
<u></u>		Claims	NO

2. Citations and explanations (Rule 70.7)

WO 2001/093160 (D1)

US 2002/0064095 (D2)

WO 2002/051354 (D3)

US 2002/0023083 (D4)

All claims are novel and involve and inventive step over the prior art. None of the cited documents, alone or in combination, disclose, or fairly suggest, all the features of claims 1-31. In particular, none of these citations teach controlling and tracking the ordering, allocation and dispensing of a pharmaceutical or device and compiling a substance inventory record, in combination with the conduct of a clinical trial, as defined in both of the independent claims, namely claims 1 and 21.